Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-15), Ashler et Manson's 9-Day RSI is 87.92.
The industry rank for Ashler et Manson's 9-Day RSI or its related term are showing as below:
XPAR:MLAEM's 9-Day RSI is ranked worse than 97.12% of 591
companies
in the Insurance industry
Industry Median: 55.5
vs XPAR:MLAEM: 87.92
Ashler et Manson (XPAR:MLAEM) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Ashler et Manson 9-Day RSI Related Terms
XPAR:MLAEM vs MRSH, AON, AJG: 9-Day RSI Comparison
For the Insurance Brokers subindustry, Ashler et Manson's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ashler et Manson 9-Day RSI vs Insurance Industry
For the Insurance industry and Financial Services sector, Ashler et Manson's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Ashler et Manson's 9-Day RSI falls into.
Ashler et Manson (XPAR:MLAEM) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ashler et Manson (XPAR:MLAEM) has a 9-Day RSI of 87.92 as of Jul. 15, 2026. According to the industry distribution chart, Ashler et Manson ranks #574 out of 591 companies in the Insurance industry, placing it in the top 97.1%.
Is Ashler et Manson's 9-Day RSI too high?
Ashler et Manson's current 9-Day RSI is 87.92. The Insurance industry median 9-Day RSI is 55.50. Ashler et Manson's value of 87.92 is 58.4% above this industry median. Based on the distribution chart, Ashler et Manson ranks #574 out of 591 companies in the Insurance industry, which is in the bottom quartile relative to peers. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's 9-Day RSI compare to MRSH and AON?
According to the Insurance industry distribution chart, Ashler et Manson ranks #574 out of 591 companies for 9-Day RSI. This places Ashler et Manson in the lower half of its industry. The industry median 9-Day RSI is 55.50. Ashler et Manson's value of 87.92 is 58.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for an Insurance company?
The median 9-Day RSI among Insurance companies is 55.50, based on 591 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ashler et Manson's current 9-Day RSI of 87.92 is 58.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Insurance industry, the median 9-Day RSI is 55.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ashler et Manson's current 9-Day RSI is 87.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.62, compared to a current price of €3.04 — trading 16% above its estimated fair value. The current 9-Day RSI is 87.92 and 58.4% above the Insurance industry median of 55.50. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current 9-Day RSI is 87.92 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?
Based on GuruFocus' analysis, Ashler et Manson stock appears to be overvalued.
The current stock price of €3.04 is trading 16% above its estimated GF Value™ of €2.62.
GuruFocus considers Ashler et Manson to be Modestly Overvalued.
Key valuation signals for XPAR:MLAEM:
9-Day RSI: 87.92
GF Value™: €2.62 vs. price of €3.04 (16% above fair value)
Industry Position: 58.4% above the Insurance median (#574 of 591)
No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLAEM has been successfully added to your 
